PillRx only · Injectable, Liposomal · Intravenous
Doxorubicin Hydrochloride
Doxorubicin Hydrochloride
5 ACTIVE SUPPLIERS — US
openFDA · updated weekly
US13 NDCs
5 active makers
5 active makers
UKComing
soon
soon
CAComing
soon
soon
AUComing
soon
soon
EUComing
soon
soon
Medicaid dispensing volumeSDUD · per quarter
Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume — Medicaid only, not all-payer.
351
Rx · 2026 Q1
8.4K
Units dispensed
-53%
Rx vs. year ago
5
Quarters · since 2025 Q1
Who makes it5 active · 0 exited
US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.
| Labeler | Type | Packages | Status |
|---|---|---|---|
| BluePoint Laboratories | unknown | 6 | SUPPLYING |
| NorthStar RxLLC | unknown | 2 | SUPPLYING |
| SUN PHARMACEUTICAL INDUSTRIES, INC. | unknown | 2 | SUPPLYING |
| Zydus Lifesciences Limited | unknown | 2 | SUPPLYING |
| Zydus Pharmaceuticals USA Inc. | unknown | 2 | SUPPLYING |
Regulatory & supply eventsFDA · US
Shortages, recalls, and registration changes attached to this drug concept.
- May 12, 2026RECALLRecall (Class I): DOXOrubin Hydrochloride Liposome injection, 50 mg/25 mL (2mg/mL), 25 mL single-dose vials, Sterile, Rx only, Manufactur…
Presence of Particulate matter: Particulate matter identified as glass. — Recalling firm: SUN PHARMACEUTICAL INDUSTRIES INC — U.S. Nationwide
- Jan 16, 2018RECALLRecall (Class II): DOXOrubicin Hydrochloride Liposome Injection, 20 mg/10 ml (2 mg/mL), 10 mL Single Use Vial, Distributed by: Sun Pharmac…
Lack Of Assurance Of Sterility — Recalling firm: Sun Pharmaceutical Industries, Inc. — Product was distributed nationwide in the USA